GLP-1 agonist drugs have gained popularity in recent years due to their effectiveness in weight loss and weight management. Our medical weight loss clinic specializes in GLP-1 agonist and GLP-1 inhibitor medications for weight loss. We can help you chose the best GLP 1 for weight loss and prescribe the GLP-1 approved for weight management.
Tired of battling stubborn excess weight with no success? Struggling to lose those 10, 20, or more pounds gained over the years? You’re not alone. At Weight Loss Clinic LA, we understand how age, life changes, and declining hormones make slimming down much harder as we age.
Modern medicine now offers new hope with targeted prescription medications that tap into your body’s own appetite signals. Exciting new drug classes like GLP-1 agonists use your natural hormones to help control hunger, boost satisfaction after meals, and stimulate effective weight loss.
To understand what GLP-1 agonists are and how they aid in weight loss, we need to understand GLP-1. GLP-1 is a hormone that your body naturally produces [1]. The main functions of GLP-1 are:
GLP-1 agonists work by mimicking the hunger-regulating hormone GLP-1 to activate receptors in the brain that suppress appetite, making you feel fuller faster, and longer. Thus, GLP-1 agonists are a powerful new class of injectable prescription medications used specifically for chronic weight management in obese and overweight adults.
GLP-1 agonists target receptors in the brain and gastrointestinal tract to influence both appetite signaling and blood sugar regulation. They activate GLP-1 receptors, which stimulate insulin release from the pancreas. Insulin allows cells throughout the body to take up glucose from food to use as energy and properly regulate blood sugar levels.
In addition, activation of GLP-1 receptors in the brain increases feelings of fullness and suppresses appetite by slowing stomach emptying and intestinal motility. This leads to reduced food intake and decreased calorie consumption overall, which drives weight loss.
By tapping into this key pathway involved in appetite regulation, GLP-1 drugs promote weight loss by:
GLP-1 agonists offer a variety of weight loss and metabolic benefits when used appropriately under medical supervision:
By activating receptors involved in appetite regulation, GLP-1 agonists suppress hunger signals and help patients feel satisfied with less food. Patients report decreased drive to eat and reduced cravings throughout the day.
GLP-1 agonists slow digestion, which promotes satiety after meals. Patients describe feeling full and content faster after starting a meal while taking these medications.
According to a systematic review and meta-analysis of randomized controlled trials published in the British Medical Journal. The study looked at people taking a GLP-1 agonist medication versus people not taking the medication over 12 months.
On average, the group taking the GLP-1 medication lost 2.3 kg (about 5 pounds) more weight than the comparison group not getting the medication. The researchers are 95% confident that people on the medication lost between 1.6 and 3 kg (3.5 to 6.5 pounds) more than those not on medication [2].
Because of substantial fat loss, weight loss reflects improved body composition – losing fat while retaining or even increasing lean muscle mass through metabolic changes.
Appetite regulation and weight effects persist with continued treatment over 1-2 years to achieve long-term weight maintenance
Contact us at +1 424-283-4273 to schedule an in office consult or virtual consult
or Book Online to receive your prescription of Wegovy or other Semaglutide or Trizepatide for weight loss.
Wegovy is an FDA-approved medication for chronic weight management in adults. In 2021, Wegovy received regulatory approval for long-term obesity treatment based on strong clinical trial efficacy and safety data.
In a 2021 research review, the efficacy of taking 2.4 mg of Wegovy weekly in weight reduction was highlighted across multiple studies, proving more effective than a placebo [3].
In separate studies involving 803 and 1,961 obese individuals, those on a 2.4 mg weekly dosage of Wegovy experienced notable reductions in body weight by 7.9% and 14.9%, respectively. Moreover, they showed improvements in waist circumference, HbA1c levels, blood pressure, total cholesterol, and triglycerides [4,5].
In a 2022 study involving 338 participants, Wegovy (semaglutide) was compared with Saxenda (liraglutide) alongside diet and exercise modifications. Over 68 weeks, Wegovy users exhibited significantly greater weight loss, attributed to reduced cravings and hunger leading to decreased food intake [6].
Compared to the placebo group following the same diet and exercise regimen, Wegovy users either prevented weight gain or exhibited more significant weight loss.
However, it’s crucial to note that the researchers of these studies received funding from Novo Nordisk, the manufacturer of Wegovy, raising potential concerns about bias and conflicts of interest.
Saxenda is an injectable GLP-1 agonist used for weight management in adults and children over 12 with obesity. It is taken daily in conjunction with diet and exercise changes. Saxenda was approved by the FDA for chronic weight management in adults in 2014, also gaining pediatric approval in 2020 based on clinical trial evidence.
In a 2021 study with 169 individuals with obesity, 62.1% experienced a minimum 5% body weight reduction within 6 months using liraglutide. Moreover, about 17.2% of those on liraglutide achieved a significant 10% reduction in body weight [7].
Another 2021 study involving 277 participants revealed that a daily 3 mg dosage of liraglutide led to an average weight loss of 9 pounds (4.1 kilograms) after 7 months, equivalent to about 4.2% of their initial body weight [8].
It’s important to note that the latter study was funded by Novo Nordisk, the manufacturer of Saxenda.
While Saxenda isn’t approved for treating type 2 diabetes, some research suggests it may aid in managing blood sugar levels [9].
Ozempic (semaglutide) is an injectable medication approved to enhance blood sugar control in adults diagnosed with type 2 diabetes. Despite being the same medication as Wegovy, Ozempic is offered in a lower dosage and is not specifically intended for weight loss purposes.
In a 2018 study involving individuals with type 2 diabetes, both high (1 mg weekly) and low (0.5 mg weekly) doses of Ozempic demonstrated greater efficacy compared to Trulicity (dulaglutide), another GLP-1 agonist. These doses effectively improved blood sugar control and led to weight reduction [10].
Similarly, a 2019 study with 577 participants diagnosed with type 2 diabetes compared the effects of Ozempic (1 mg per week) and Victoza (liraglutide), a daily-administered GLP-1 agonist, over 30 weeks. Notably, Ozempic not only proved more efficient in long-term blood sugar management but also resulted in participants losing more than three times the amount of weight [11].
It’s important to note that Novo Nordisk, the manufacturer of Ozempic, funded both of these studies.
The FDA recently approved a new GLP-1 agonist medication called Mounjaro (tirzepatide) for adults with type 2 diabetes. This once-weekly injectable drug was designed to help manage blood sugar levels in combination with diet, exercise, and other diabetes treatments. Mounjaro is mainly prescribed for managing blood sugar levels. However, one study suggests that it can facilitate weight loss with proper diet and exercise.
In a 2022 study examining the impact of once-weekly tirzepatide doses (5 mg, 10 mg, and 15 mg) on individuals with obesity or overweight and at least one weight-related condition, results after 72 weeks showed average weight reductions of 15%, 19.5%, and 20.9% for the respective dosage groups [12].
Most patients notice some appetite and eating habit changes within a few weeks. Early weight loss of around 5% may occur in the first 3 months. Maximum results take upwards of 9-12 months for full effects on body weight.
Yes, lifestyle modifications are critical for success! GLP-1 drugs enhance your body’s natural appetite signals, but dietary changes and increased activity maximize weight loss outcomes.
Costs range from $1000-1500 monthly without insurance. Some plans do cover, often with prior authorization needed. Manufacturer savings cards can provide co-pay assistance for those with coverage.
GLP-1 drugs are approved for chronic long-term treatment, not just short-term use. Maintaining weight loss requires prolonged use in most patients for 1-2 years or potentially longer under medical supervision.
Certain interactions may exist, especially with diabetes medications, so your provider must review your full drug regimen before starting.
If you develop persistent, severe side effects or fail to respond with at least 5% weight loss in 3-6 months, your prescriber may reassess suitability and explore alternative therapies or interventions.
Weight Loss Clinic LA offers the best GLP-1 Agonist near me in Beverly Hills but can also come to your home or office throughout the Los Angeles area. We serve patients near Beverly Hills, Bel Air, West Hollywood, Santa Monica, West Los Angeles, Culver City, Hollywood, Venice, Marina del Rey, Malibu, Manhattan Beach, Redondo Beach, Downtown Los Angeles, Encino, Woodland Hills, Sherman Oaks, Calabasas, Burbank, Glendale, Hidden Hills, Agoura Hills, Northridge, North Hollywood, Topanga, Canoga Park, Reseda, Valley Glen, Chatsworth, West Hills, Winnetka, Universal City, Silverlake, Echo Park, and many more.
"*" indicates required fields
At Weight Loss Clinic LA we are dedicated to providing our clients with the best treatment plans tailored to your personal weight loss goals with the newest technology available to the market.
Copyright © 2024 Weight Loss Clinic Los Angles | All Rights Reserved.
